Irritable bowel syndrome

被引:5
|
作者
Joel A. Sach
Lin Chang
机构
[1] UCLA/CURE Neuroenteric Disease Program,
关键词
Irritable Bowel Syndrome; Main Drug Interaction; Irritable Bowel Syndrome Patient; Loperamide; Tegaserod;
D O I
10.1007/s11938-002-0049-3
中图分类号
学科分类号
摘要
Because treatment of irritable bowel syndrome (IBS) patients can be frustrating to the clinician and patient as well, the physician should strive to gain the patient’s confidence with a concise, appropriate work-up and by offering reassurance and education that IBS is a functional disorder without significant long-term health risks.First-line treatment should be aimed at treating the most bothersome symptom.Tricyclic antidepressants are superior to placebo in reducing abdominal pain scores, as well as improving global symptom severity [1••].Loperamide is superior to placebo in managing IBS-associated diarrhea [2••].Whereas fiber has a role in treating constipation, its value for IBS or, specifically, in the relief of abdominal pain or diarrhea associated with IBS is controversial [2••].Although certain antispasmodics have demonstrated superiority over placebo in managing abdominal pain, none of these agents are available in the United States [3••].Probiotic therapy using Lactobacillus plantarum has demonstrated superiority to placebo in improving pain, regulating bowel habits, and decreasing flatulence [4].As studied in a recent placebo-controlled prospective study, Chinese herbal medicines significantly improved bowel symptom scores and global symptom profile, and reduced IBS-related quality of life impairment [5].Some of the most promising emerging therapies in IBS revolve around targeted pharmacotherapeutic modulation of serotonin receptors (ie, 5-HT3 and 5-HT4 subtypes), which are involved in sensory and motor functions of the gut. Other investigational agents that are also being explored include cholecystokinin antagonists, α2-adrenergic agonists (eg, clonidine), serotonin reuptake inhibitors (eg, citalopram), and neurokinin antagonists [6].IBS is best understood through the biopsychosocial paradigm, and therefore, its effective management requires a comprehensive multidisciplinary approach based on patient education and reassurance, enhanced by diet recommendations and lifestyle modifications, and complemented by pharmacotherapy and psychosocial intervention in more severe cases.
引用
收藏
页码:267 / 278
页数:11
相关论文
共 50 条
  • [1] Irritable Bowel Syndrome
    Antonella Spinelli
    Clinical Drug Investigation, 2007, 27 : 15 - 33
  • [2] Irritable bowel syndrome
    Arnold Wald
    Current Treatment Options in Gastroenterology, 1999, 2 (1) : 13 - 19
  • [3] Postinfectious irritable bowel syndrome
    Kok-Ann Gwee
    Current Treatment Options in Gastroenterology, 2001, 4 (4) : 287 - 291
  • [4] New approaches to the medical treatment of irritable bowel syndrome
    Driss Berrada
    Katia Canenguez
    Tony Lembo
    Current Gastroenterology Reports, 2003, 5 (4) : 337 - 342
  • [5] Genes and irritable bowel syndrome: Is there a link?
    Saito Y.A.
    Current Gastroenterology Reports, 2008, 10 (4) : 355 - 362
  • [6] Advances in the management of irritable bowel syndrome
    Brooks D. Cash
    William D. Chey
    Current Gastroenterology Reports, 2003, 5 (6) : 468 - 475
  • [7] Irritable bowel syndrome: Is it "irritable brain" or "irritable bowel"?
    Padhy, Susanta Kumar
    Sahoo, Swapnajeet
    Mahajan, Sonali
    Sinha, Saroj Kumar
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2015, 6 (04) : 568 - 577
  • [8] Current insights in to the pathophysiology of Irritable Bowel Syndrome
    Theodoros Karantanos
    Theofano Markoutsaki
    Maria Gazouli
    Nicholas P Anagnou
    Dimitrios G Karamanolis
    Gut Pathogens, 2
  • [9] Costs of irritable bowel syndrome in the UK and US
    Stefanie Maxion-Bergemann
    Frank Thielecke
    Florian Abel
    Rito Bergemann
    PharmacoEconomics, 2006, 24 (1) : 21 - 37
  • [10] Treatment of irritable bowel syndrome
    Robin C. Spiller
    Current Treatment Options in Gastroenterology, 2003, 6 (4) : 329 - 337